Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2018-07

    • Cefotaxime: A Lactamase-Resistant Cephalosporin for Antim...

    2026-03-23

    Cefotaxime: A Lactamase-Resistant Cephalosporin for Antimicrobial Research

    Executive Summary: Cefotaxime is a third-generation cephalosporin antibiotic with demonstrated resistance to beta-lactamase enzymes, making it indispensable for studies on both Gram-positive and Gram-negative bacterial infections (APExBIO product page). Its stability and broad-spectrum action are validated by peer-reviewed research and benchmarking against multidrug-resistant strains (Chen et al., 2025). The product BA1012 from APExBIO is supplied as a solid, with a molecular weight of 455.47 and a formula of C16H17N5O7S2. Correct storage at -20°C preserves its efficacy. Cefotaxime's performance in antimicrobial resistance (AMR) research is further supported by its inclusion in global surveillance and experimental protocols.

    Biological Rationale

    Cefotaxime is classified as a third-generation cephalosporin antibiotic. It is widely used in laboratory settings to investigate mechanisms of bacterial pathogenesis and resistance (APExBIO). Its resistance to beta-lactamase enzymes allows it to retain activity where first- and second-generation cephalosporins fail. This property is critical in studies of multidrug-resistant Enterobacteriaceae, including carbapenem-resistant Enterobacter cloacae (Chen et al., 2025). Cefotaxime’s broad-spectrum efficacy encompasses most Gram-negative rods (e.g., Enterobacteriaceae), and clinically relevant Gram-positive cocci. Its molecular structure hinders enzymatic degradation, making it a model compound for both basic and applied AMR research.

    Mechanism of Action of Cefotaxime

    Cefotaxime exerts its antibacterial effect by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs), specifically interfering with the final transpeptidation step of peptidoglycan cross-linking (NCBI Bookshelf). This action leads to cell lysis and bacterial death, classifying cefotaxime as a bactericidal antibiotic. Beta-lactamase resistance is achieved via structural modifications to the beta-lactam ring, reducing hydrolysis by common beta-lactamases. Its spectrum includes both Gram-positive and Gram-negative bacteria, with high activity against Enterobacteriaceae and Streptococcus spp. However, it is ineffective against most Pseudomonas aeruginosa and certain Enterococcus species due to intrinsic resistance mechanisms (NCBI).

    Evidence & Benchmarks

    • 85.19% of carbapenem-resistant Enterobacter cloacae isolates from eight hospitals in Guangdong Province, China, carried carbapenemase-encoding genes, demonstrating a high prevalence of multidrug resistance (Chen et al., 2025).
    • Cefotaxime exhibits potent in vitro activity against most Enterobacteriaceae, with minimum inhibitory concentrations (MICs) typically ≤1 μg/mL for susceptible strains (NCBI Bookshelf).
    • Stability studies confirm that cefotaxime loses efficacy after prolonged storage in solution, supporting the recommendation for fresh preparation and storage at -20°C as a solid (APExBIO).
    • The BA1012 product from APExBIO is validated for use in antimicrobial resistance screening protocols, supporting reproducibility in laboratory experiments (TCEPhydrochloride.com).

    Applications, Limits & Misconceptions

    Cefotaxime is a cornerstone for AMR research, particularly in the context of carbapenem-resistant Enterobacteriaceae and related Gram-negative bacteria. It is used to:

    • Model antibiotic pressure in bacterial infection models.
    • Screen for beta-lactamase-mediated resistance mechanisms.
    • Benchmark new antimicrobial agents against established standards.

    For a more scenario-driven analysis of cefotaxime in research, see our companion article (Cefotaxime (SKU BA1012): Reliable Cephalosporin Solutions), which focuses on troubleshooting and practical application. This article extends those findings with updated surveillance data and genetic context from recent hospital-based studies.

    Common Pitfalls or Misconceptions

    • Not effective against all beta-lactamase types: Cefotaxime resists most but not all beta-lactamases; extended-spectrum beta-lactamases (ESBLs) and certain carbapenemases can hydrolyze it (Chen et al., 2025).
    • Not suitable for clinical or diagnostic use: APExBIO's cefotaxime BA1012 is designated for research only and is not for therapeutic administration (APExBIO).
    • Loss of activity in solution: Pre-made solutions of cefotaxime degrade rapidly, losing potency; always use freshly prepared solutions.
    • Does not cover all pathogens: Ineffective against Pseudomonas aeruginosa and most Enterococcus spp. due to intrinsic resistance.
    • Storage errors: Storing at temperatures above -20°C leads to decreased stability and activity.

    Workflow Integration & Parameters

    Cefotaxime (SKU BA1012) from APExBIO is supplied as a solid, with a molecular weight of 455.47 g/mol and a formula of C16H17N5O7S2. For experimental use, it should be dissolved in sterile water or buffer immediately before application. Long-term storage of dissolved cefotaxime is not recommended. The solid should be stored at -20°C, and shipping is performed under cold chain conditions using blue ice. Standard working concentrations in susceptibility assays are 1–64 μg/mL, depending on the bacterial strain and study design (APExBIO). Integration into AMR workflows includes use in broth microdilution, disk diffusion, and bacterial killing curve assays. When benchmarking new agents or resistance mechanisms, cefotaxime serves as a validated control compound.

    Conclusion & Outlook

    Cefotaxime remains an essential tool for antimicrobial resistance research, particularly for studies involving Gram-negative rods and beta-lactamase-mediated resistance. Its robust activity profile, validated storage guidelines, and consistent performance in standardized assays underpin its widespread use in research laboratories. As the prevalence of multidrug-resistant pathogens continues to rise, reagents like cefotaxime BA1012 from APExBIO will be critical for accurate modeling and surveillance of bacterial resistance. Future research will benefit from integrating genomic surveillance with phenotypic assays to track evolving resistance patterns and validate new antimicrobial agents (Chen et al., 2025).